Description: Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.
Home Page: www.anavex.com
AVXL Technical Analysis
630 5th Avenue
New York,
NY
10111
United States
Phone:
844 689 3939
Officers
| Name | Title |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | Chairman, Pres, CEO & Sec. |
| Ms. Sandra Boenisch CPA, CPA, CGA | Principal Financial Officer & Treasurer |
| Mr. Stephan Toutain | Chief Operating Officer |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer |
| Dr. Emmanuel O. Fadiran RPh, Ph.D. | Sr. VP of Regulatory Affairs |
| Clint Tomlinson | VP of Corp. |
| Dr. Adebayo Laniyonu Ph.D. | Sr. VP of Nonclinical Devel. |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8312 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2006-08-02 |
| Fiscal Year End: | September |
| Full Time Employees: | 38 |